9Bio: advancing AI-driven antibody discovery
9Bio uses experimental measurements of engineered antibodies to inform its AI-driven optimization program. Its traditional binding systems required specialist equipment and trained operators, adding time and cost to the work.
First-generation radiolabeled cyclic peptides for imaging PDGFRα
First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α — The researchers investigated cyclic peptides targeting PDGFRα, using VICA™ for label-free binding assessment within the broader experimental program. Its contribution was the binding measurement across candidate cyclic peptides; the downstream radiotracer imaging work used orthogonal methods.
Measuring protein binding through colour changes
Published in npj Biosensing in December 2024, this study demonstrated how VICA™ can measure protein interactions without fluorescent or enzymatic labels.
Apolipoprotein A1 transports and regulates MMP2 in the blood
Apolipoprotein-A1 transports and regulates MMP2 in the blood — In this investigation of apolipoprotein A1 and matrix metalloproteinase-2 (MMP2), researchers used VICA™ to examine direct binding interactions between the proteins. Those label-free measurements were combined with orthogonal experimental methods in reaching the study’s broader biological findings.
Testing VICA™ in a commercial feedlot
A cattle-health study tested VICA™ in field conditions to measure an inflammation marker associated with respiratory disease.
VICA™ installed at MolScreen
Pavonis’s label-free protein interaction technology is available to researchers through MolScreen at the University of Alberta.